Analysis of antiviral efficacy in initial treatment of CHB patients with abnormal ALT
Objective To analyze the curative effect of antiviral therapy in CHB patients with abnormal ALT under the new guidelines.Methods Newly treated CHB patients from Kunming Third People's Hospital from April 2020 to April 2024 were selected to analyze the changes of clinical indicators in the treated group and the untreated group.Results 1.HBV-DNA load and HBsAg titer at 48 weeks in the treated group were lower than those before treatment,the difference was statistically significant(P＜0.05),while the untreated group showed an increasing trend,the difference was not statistically significant(P＞0.05).2.ALT,TBIL,GGT and AFP at 48 weeks in the treatment group were significantly lower than before treatment,and GGT in the high viral load group had statistically significant difference from baseline(P＜0.05),while ALT and AFP were significantly higher than baseline in the untreated group at 48 weeks,and the AFP value was significantly higher than baseline,with statistical significant difference(P＜0.05).3.ALT relapse rates in patients with high and low viral load were 46.15％(24/52)and 57.41％(31/54)in the treated group,and 9.52％(4/42)in the untreated group.4.APRI and FIB-4 of patients with high viral load in the treatment group were decreased by 0.04 and 0.01 from baseline,respectively,with statistical significant difference(P＜0.05).Conclusions The HBV-DNA load,biochemical indexes and degree of liver fibrosis at 48 weeks in the treatment group were significantly improved compared with those in the untreated group,and antiviral therapy for initial treatment of CHB patients with abnormal ALT could benefit from the new guidelines.
万方数据
维普
